Delphian Therapeutics

Delphian Therapeutics is a clinical-stage company, unlocking the full therapeutic potential of endocannabinoid system (ECS) modulation to treat large, poorly managed pain and neurological disorders. Funded by the U.S. National Institutes of Health, we are leveraging the science of natural cannabinoids to develop optimized medicines for FDA and EMA approval, starting with migraine. The ECS is a a vast network of ligands and proteins and high-level regulator of multiple biological systems. Highly selective CB1 or CB2 targeting holds limited promise to modulate the system to its full therapeutic potential. Instead, ECS modulation is optimized by targeting multiple sites at once, using compounds that have extremely well-established safety profiles. Delphian is funded in part by the Migraine Research Foundation and the U.S. National Institutes of Health.